Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?

被引:26
|
作者
Inal, Ali [1 ]
Kaplan, M. Ali [1 ]
Kucukoner, Mehmet [1 ]
Urakci, Zuhat [1 ]
Kilinc, Faruk [2 ]
Isikdogan, Abdurrahman [1 ]
机构
[1] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey
[2] Dicle Univ, Div Endocrinol, Diyarbakir, Turkey
关键词
Diabetes mellitus; Non-small cell lung; cancer; Prognostic factors; COLORECTAL-CANCER; LONGER SURVIVAL; GLUCOSE LEVEL; RISK; NSCLC; PREVALENCE; MORTALITY; IMPACT; BLOOD;
D O I
10.1016/j.rppneu.2013.09.001
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: It has been demonstrated that there are a lot of different prognostic factors which Non-small cell lung are worthy of consideration whereas diabetes mellitus (DM) has not been clearly or consistently identified as a prognostic value in advanced non-small cell lung cancer (NSCLC). The aim Prognostic factors of this study was to investigate the prognostic significance of the characteristics of patients in advanced NSCLC. Specifically, we investigated the impact of DM for progression-free survival (PFS) and overall survival (OS) in patients receiving first-line platinum-based doublets chemotherapy. Methods: We retrospectively reviewed 442 patients with advanced NSCLC. DM and other potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for OS were identified as having prognostic significance: performance status (p < 0.001), stage (p < 0.001), DM (p < 0.001), liver metastasis (p = 0.02) and brain metastasis (p < 0.001). Stage, diabetes mellitus, and liver metastasis were identified as having prognostic significance for PFS. Multivariate analysis showed that poor performance status, presence of DM and advanced stage were considered independent negative prognostic factors for OS (p 0.001, p < 0.001 and p < 0.001 respectively). Furthermore, DM and stage were considered independent negative prognostic factors for PFS (p 0.005 and p 0.001 respectively). Conclusion: In conclusion, DM at the time of diagnosis was associated with the negative prognostic importance for PFS and OS in the advanced stage patients who were receiving first-line platinum-based doublets chemotherapy. In addition poor performance status and advanced stage were identified as negative prognostic factors. (c) 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 50 条
  • [21] New Agents in Advanced Non-Small-Cell Lung Cancer Treatment
    Ricciardi, Serena
    de Marinis, Filippo
    ONCOLOGY, 2009, 77 : 103 - 112
  • [22] Overview of advanced non-small-cell lung cancer treatment in Mexico
    Víctor Lira Puerto
    BMC Proceedings, 2 (Suppl 2)
  • [23] Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer
    Mok, Tony
    Lee, Kirsty
    Tang, Michael
    Leung, Linda
    FUTURE ONCOLOGY, 2014, 10 (05) : 813 - 822
  • [24] Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role?
    Kalemkerian, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1325 - 1326
  • [25] Treatment and prognosis of advanced stage non-small-cell lung cancer
    Ben Abdallah, F. Chermiti
    Ben Ali, G.
    Boudaya, M. Sadok
    Mlika, M.
    Chtourou, A.
    Taktak, S.
    Ben Kheder, A.
    REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (03) : 214 - 220
  • [26] Treatment of advanced non-small-cell lung cancer in special populations
    Lilenbaum, Rogerio C.
    ONCOLOGY-NEW YORK, 2004, 18 (10): : 1321 - 1325
  • [27] Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer
    Reck, Martin
    Rabe, Klaus F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 849 - 861
  • [28] Salvage treatment with apatinib for advanced non-small-cell lung cancer
    Song, Zhengbo
    Yu, Xinmin
    Lou, Guangyuan
    Shi, Xun
    Zhang, Yiping
    ONCOTARGETS AND THERAPY, 2017, 10 : 1821 - 1825
  • [29] TREATMENT IND FOR ADVANCED NON-SMALL-CELL LUNG-CANCER
    NIGHTINGALE, SL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23): : 1818 - 1818
  • [30] Role of immunotherapy in the treatment of advanced non-small-cell lung cancer
    Rijavec, Erika
    Genova, Carlo
    Alama, Angela
    Barletta, Giulia
    Sini, Claudio
    Pronzato, Paolo
    Coco, Simona
    Dal Bello, Maria Giovanna
    Savarino, Graziana
    Truini, Anna
    Boccardo, Francesco
    Grossi, Francesco
    FUTURE ONCOLOGY, 2014, 10 (01) : 79 - 90